The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives

Abstract

Various antihypertensive treatment regimens, chosen as part of usual care, might distinguish in their clinical efficacy. Pharmacological modeling of high-level activity of the renin-angiotensin system (RAS) in arterial hypertension often makes it possible to effectively monitor patients with elevated blood pressure (BP). The aim of the mini review is summarize knowledge regarding perspectives to use of combined antihypertensive drug contained the direct renin inhibitor (aliskiren) and selective 1-blocker (nebivolol). However, the data regarding coadministration of both drugs are very limited. Recent pre-clinical studies have been shown that concomitant co-administration of aliskiren and nebivolol given in fixed combination did not form any active chemical complexes with novel pharmacological abilities. The clinical data are confirmed a high BP lowering activity of fixed combination of aliskiren and nebivolol associated with desirable level of tolerability and safety. The review is concluded that there is rationale of creating a combined remedy containing aliskiren (150 mg) and nebivolol (5 mg). High BP lowering efficacy, safety and tolerability of aliskiren and nebivolol combined drug in hypertensive patients might emphasize the great potential of its clinical application 108 Gregoriy А. Ignatenko et al.